Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: A Nationwide VA cohort study
Fecha
2020Autor
Patel, Dhruvan
Xie, Dawei
Lewis, James
Documentos PDF
Imagenes y Videos
Resumen
The recent outbreak of novel Coronavirus disease 2019 (COVID-19) has become a pandemic and
is threatening global health.1
The highest number of COVID-19 confirmed cases were reported
in the United States, with 1.47 million confirmed cases and 89,272 deaths as of 05/19/2020.2
Inflammatory bowel disease (IBD) is primarily treated by immunosuppressive medications
which can put patients at risk of developing infectious complications including viral infections.3
Therefore, it is important to evaluate the risk factors of COVID-19 in the IBD population,
especially the impact of immunosuppression on the incidence. There are limited data available
in the current literature on this topic.
Our aim was to evaluate the impact of Anti-TNF and thiopurines on the development of COVID19 in a nationwide cohort of IBD patients in the Veterans’ Affairs Healthcare System (VAHS).
The VAHS is the largest integrated healthcare system in the US, serving up to 9 million Veterans
each year
Palabras clave
Anti-TNF; Thiopurines medications; COVID-19; Patients with inflammatory bowel diseaseEnlace al recurso
https://doi.org/10.1053/j.gastro.2020.05.065Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.